Survey of Procedures and Resources for Initiating Treatment of HIV in Africa-Zambia
SPRINT-Zambia
2 other identifiers
observational
2,189
1 country
1
Brief Summary
In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization (WHO) called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for HIV. However, to date neither the WHO nor the Zambia Ministry of Health has provided detailed guidance on how to implement this recommendation. In sub-Saharan Africa, where most HIV patients are located, studies continue to document high losses of treatment-eligible patients from care before they receive their first dose of antiretroviral medications (ARVs). Among facility-level reasons for these losses are treatment initiation protocols that require multiple clinic visits and long waiting times before a patient who tests positive for HIV is dispensed an initial supply of medications. There is very little published evidence on the practical details of the process and the extent to which it varies by facility, setting, or country. Without a robust baseline evidence base, it is challenging to identify opportunities for making improvements. The SPRINT (Survey of Procedures and Resources for Initiating Treatment of HIV in Africa) study will begin to develop this evidence base. SPRINT will combine a facility-level description of the standard of care with a retrospective record review of patients who recently initiated ART at the study sites. Data will be collected from 12 health facilities in Zambia. The survey will elicit detailed information about current procedures through structured interviews with clinic staff at the selected health facilities. The record review for a retrospective cohort of patients eligible for ART will estimate actual numbers of clinic visits, services provided, and duration of the steps for treatment initiation from start to finish. SPRINT is expected to identify differences in approaches to treatment initiation and potential opportunities for improvement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 9, 2020
CompletedFirst Posted
Study publicly available on registry
July 14, 2020
CompletedStudy Start
First participant enrolled
September 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 30, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2024
CompletedDecember 27, 2024
December 1, 2024
8 months
July 9, 2020
December 22, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Average numbers of visits required to start ART
Number of health system interactions required between HIV diagnosis and first dispensing of ARVs
Up to 6 months after treatment eligibility determined
Time to ART initiation
Average number of days required between HIV diagnosis and first dispensing
Up to 6 months after treatment eligibility determined
Secondary Outcomes (1)
Proportion of patients who initiate by specified time intervals
Up to 6 months after treatment eligibility determined
Other Outcomes (1)
Procedures for ART initiation
Up to 6 months after treatment eligibility determined
Study Arms (2)
Patients who initiated HIV treatment
Service providers at study facilities
Interventions
The study will collect routine medical record data from the electronic medical record system, other electronic databases, and paper charts.
Clinicians and lay staff will be interviewed regarding the ART initiation process.
Eligibility Criteria
Patients who became eligible for ART at a study facility between 1 July 2018 and 30 June 2019.
You may qualify if:
- ≥18 years old
- HIV-positive
You may not qualify if:
- Pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Boston Universitylead
- Bill and Melinda Gates Foundationcollaborator
- University of Witwatersrand, South Africacollaborator
- Clinton Health Access Initiative Inc.collaborator
Study Sites (2)
Health Economics and Epidemiology Research Office
Johannesburg, Gauteng, 2193, South Africa
Clinton Health Access Initiative
Lusaka, Zambia
Related Publications (1)
Huber A, Hirasen K, Brennan AT, Phiri B, Tcherini T, Mulenga L, Haimbe P, Shakwelele H, Nyirenda R, Wilson Matola B, Gunda A, Rosen S. Uptake of same-day initiation of HIV treatment in Malawi, South Africa, and Zambia as reported in routinely collected data: the SPRINT retrospective cohort study. Gates Open Res. 2023 May 2;7:42. doi: 10.12688/gatesopenres.14424.2. eCollection 2023.
PMID: 37153118BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sydney B Rosen, MPA
BU School of Public Health
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 9, 2020
First Posted
July 14, 2020
Study Start
September 15, 2020
Primary Completion
April 30, 2021
Study Completion
December 1, 2024
Last Updated
December 27, 2024
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share